Date: <u>2022-03-10</u>	
Your Name: _Jiaxi	<u>1 Li</u>
Manuscript Title:	Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Tri	o mrna

Manuscript number (if known): __ATM-22-1289_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423)	Funding

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
-		V N	
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
44	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Descipt of equipment	V. Nana	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10	
Your Name: _Jieshan Chen	
Manuscript Title: _ Downregulate	d ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA	
Manuscript number (if known):	ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
pro	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423)	Funding

		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Mingyi Zhao
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423) Time frame: past	Funding

2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Zhetao Li
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423) Time frame: past	Funding

2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Nanbo Liu
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423) Time frame: past	Funding

2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Heng Fang
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423)	Funding
Time frame: past 36 months			

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	benamb		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Miaoxian Fang
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423) Time frame: past	Funding

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	ō .		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	XNone	
13	Descipt of anylogenet	V. Nana	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	^_NUTIE	
	illialiciai illici ests		

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _ <u>2022-03-10</u>
our Name: _Ping Zhu
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289
• • • • • • • • • • • • • • • • • • • •

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423)	Funding
Time frame: past 36 months			

Grants or contracts from	XNone	
any entity (if not indicated		
in item #1 above).		
Royalties or licenses	XNone	
Consulting fees	XNone	
Payment or honoraria for	XNone	
	XNone	
testimony		
	XNone	
,		
Patents planned, issued or	XNone	
pending		
	XNone	
•		
	XNone	
_		
	X None	
•		
Receipt of equipment,	XNone	
materials, drugs, medical		
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	any entity (if not indicated in item #1 above). Royalties or licenses Consulting fees Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	any entity (if not indicated in item #1 above). Royalties or licenses

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

Date: _2022-03-10
Your Name: _Liming Lei
Manuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6A
modification of Trio mRNA
Manuscript number (if known): ATM-22-1289

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article processing charges, etc.) No time limit for this item.	High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016)	Funding
		National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM)	Funding
		Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423) Time frame: past	Funding

2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	·		
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	ō ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement:

ate: _2022-03-10				
Your Name: _Chunbo Chen				
Ianuscript Title: _ Downregulated ALKBH5 contributes to myocardial ischemia/reperfusion injury by increasing m6/				
modification of Trio mRNA				
Manuscript number (if known): ATM-22-1289				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Ī	
1	All support for the present manuscript (e.g., funding, provision of study materials,	Maoming Science and Technology Program (2020KJZX003)	Funding
	medical writing, article	High-Level Hospital Construction Research	Funding
	processing charges, etc.) No time limit for this item.	Project of Maoming	
	No time mint for this item.	People's Hospital	
		(zx2020016)	
		National Natural Science	Funding
		Foundation of China	
		(82100275 to Liu NB;	
		81900285 to Lei LM)	
		Special Project of	Funding
		Dengfeng Program of	
		Guangdong Provincial	
		People's Hospital	
		(DFJH201812,	
		KJ012019119, and	
		KJ012019423) Time frame: past	26 manths

Grants or contracts from	XNone	
any entity (if not indicated		
in item #1 above).		
Royalties or licenses	XNone	
Consulting fees	XNone	
Payment or honoraria for	XNone	
l	XNone	
testimony		
	XNone	
, ,		
Patents planned, issued or	XNone	
pending		
Participation on a Data	XNone	
•		
l	XNone	
_		
	X None	
·		
Receipt of equipment,	XNone	
materials, drugs, medical		
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	any entity (if not indicated in item #1 above). Royalties or licenses Consulting fees Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	any entity (if not indicated in item #1 above). Royalties or licenses

This work was supported by the Maoming Science and Technology Program (2020KJZX003), the High-Level Hospital Construction Research Project of Maoming People's Hospital (zx2020016), National Natural Science Foundation of China (82100275 to Liu NB; 81900285 to Lei LM), and the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, and KJ012019423).

Please place an "X" next to the following statement to indicate your agreement: